Reviewing Fortress Biotech (NASDAQ:FBIO) and Milestone Pharmaceuticals (NASDAQ:MIST)

Fortress Biotech (NASDAQ:FBIO) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Fortress Biotech and Milestone Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1	1	2	0	2.25
Milestone Pharmaceuticals	1	1	4	1	2.71

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 750.00%. Milestone Pharmaceuticals has a consensus price target of $6.40, suggesting a potential upside of 710.54%. Given Fortress Biotech’s higher probable upside, equities analysts plainly believe Fortress Biotech is more favorable than Milestone Pharmaceuticals.

Risk & Volatility

Fortress Biotech has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Profitability

This table compares Fortress Biotech and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Institutional and Insider Ownership

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Fortress Biotech and Milestone Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26 million	1.05	$6.82 million	$2.64	0.76
Milestone Pharmaceuticals	$1.55 million	63.42	-$63.06 million	($0.69)	-1.14

Fortress Biotech has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Fortress Biotech beats Milestone Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About Fortress Biotech

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company’s early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.